Asset sale Pending

TransCode Therapeutics acquisition of Unleash-owned rights to UIO-524, UIO-525 and UIO-526

Announced 3 Mar 2026

Advisers

Unleash-owned rights to UIO-524, UIO-525 and UIO-526

Target

Not disclosed

TransCode Therapeutics

Acquirer

Not disclosed

Other advisers

Financial adviser
Target
Unleash-owned rights to UIO-524, UIO-525 and UIO-526
Acquirer
TransCode Therapeutics
Seller
Unleash Immuno Oncolytics
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.